Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primatesResearch in context

Summary: Background: The emergence of antigenically distinct SARS-CoV-2 variants increases the risk of immune escape and requires continually updated vaccines. In addition, short-lived specific immunity is a limitation faced by current COVID-19 mRNA vaccines against Sarbecoviruses. This underscores...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Romain Marlin, Mireille Centlivre, Laetitia Bossevot, Anne-Sophie Gallouët, Marie Alexandre, Delphine Planas, Mariangela Cavarelli, Isabelle Staropoli, Wesley Gros, Mathieu Surenaud, Craig Fenwick, Sylvain Cardinaud, Mathilde Galhaut, Sandra Zurawski, Victor Magneron, Loïc Pintore, Cécile Hérate, Marie-Anne Rameix Welti, Paul Mazet, Vanessa Contreras, Francis Relouzat, Nathalie Dereuddre-Bosquet, Giuseppe Pantaleo, Rodolphe Thiébaut, Mélanie Prague, Olivier Schwartz, Gerard Zurawski, Véronique Godot, Roger Le Grand, Yves Lévy
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2026-07-01
Rangatū:	EBioMedicine
Ngā marau:	Preclinical study Immunogenicity SARS-CoV-2 vaccine candidate Non-human primate Dendritic cell targeting vaccine CD40
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2352396426002446
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!